Is Moderate HIV Viremia Associated With a Higher Risk of Clinical Progression in HIV-Infected People Treated With Highly Active Antiretroviral Therapy
- 1 January 2006
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 41 (1), 23-30
- https://doi.org/10.1097/01.qai.0000188337.76164.7a
Abstract
To assess the risk of clinical progression (CP) according to the duration of time spent without complete viral load (VL) suppression compared with that associated with periods of stably suppressed viremia in HIV-infected people who started highly active antiretroviral therapy (HAART) when previously naïve to antiretrovirals. A cohort study of patients having started HAART after enrollment in the Italian Cohort of Antiretroviral-Naive Patients (ICoNA) and being followed for at least 6 months. Person-years spent in different categories according to the VL level and the change in VL from the most recent value before the initiation of HAART were calculated. A multivariable Poisson regression model, including potential confounders, was constructed. A total of 3023 patients were studied. The overall rate of CP was 13.4 per 1000 person-years. Evidence for a higher risk of CP was observed for people with a current VL >10,000 copies/mL. For each year longer spent on HAART with a VL >100,000 copies/mL, a 5-fold increased risk was observed (relative risk [RR] = 5.34, 95% confidence interval [CI]: 2.83 to 1.08; P = 0.0001). An increased risk of CP in patients with current suppression 3 log10 copies/mL, although it was not significant. Longer duration on HAART with a VL suppressed below set point seemed to confer protection against CP. Virologic failure to antiretroviral drugs is common. The risk of CP may remain low despite a low but detectable level of HIV viremia.Keywords
This publication has 26 references indexed in Scilit:
- Interruption of Highly Active Antiretroviral Therapy in HIV Clinical PracticeJAIDS Journal of Acquired Immune Deficiency Syndromes, 2005
- Antiretroviral Resistance among HIV‐Infected Persons Who Have Died in British Columbia, in the Era of Modern Antiretroviral TherapyThe Journal of Infectious Diseases, 2004
- Strong Cell‐Mediated Immune Responses Are Associated with the Maintenance of Low‐Level Viremia in Antiretroviral–Treated Individuals with Drug‐Resistant Human Immunodeficiency Virus Type 1The Journal of Infectious Diseases, 2004
- HIV-1–Infected Antiretroviral-Treated Patients With Prolonged Partial Viral SuppressionJAIDS Journal of Acquired Immune Deficiency Syndromes, 2003
- Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapyAIDS, 2003
- Predictors of Long‐Term Increase in CD4+Cell Counts in Human Immunodeficiency Virus–Infected Patients Receiving a Protease Inhibitor–Containing Antiretroviral RegimenThe Journal of Infectious Diseases, 2002
- Transient Relapses (“Blips”) of Plasma HIV RNA Levels During HAART Are Associated With Drug ResistanceJAIDS Journal of Acquired Immune Deficiency Syndromes, 2001
- Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patientsAIDS, 2000
- Sustained CD4+T Cell Response after Virologic Failure of Protease Inhibitor–Based Regimens in Patients with Human Immunodeficiency Virus InfectionThe Journal of Infectious Diseases, 2000
- In vivo emergence of HIV-1 variants resistant to multiple protease inhibitorsNature, 1995